CAR-T Cell Therapy
in China:
Approved. Accessible.

All 9 NMPA-approved CAR-T products (Axi-cel, Relma-cel, Equecab-cel, Inaticabtagene autoleucel, Zevor-cel, Cilta-cel, Renialeucel, Puzolcabtagene autoleucel, and Satri-cel) are manufactured at GMP-certified facilities under regulatory standards equivalent to FDA GMP requirements. These are not counterfeit or lower-quality versions; they are independently developed and clinically validated products that completed full Phase III trials in China before NMPA approval.

The main risk factor in CAR-T therapy globally is Cytokine Release Syndrome (CRS). Chinese CAR-T centres, particularly high-volume institutions like SYSUCC and Nanfang Hospital, have developed extensive CRS management protocols. In some respects their experience managing complications exceeds many Western centres, simply due to volume.

We want to be direct about this, based on our ongoing communication with hospitals and research teams in China. Participation by international patients is not prohibited in principle, but enrollment into investigator-initiated CAR-T trials is highly selective. Recruitment is typically managed directly by the research team at the public hospital running the trial, and available places are often offered first to patients already receiving care there or referred through domestic clinical networks.

As a result, enrollment by overseas patients with no prior treatment history in China remains relatively uncommon — even when a patient appears medically eligible on paper. Admission is ultimately decided by the investigators and the study protocol, not guaranteed by eligibility alone. If a commercial NMPA-approved product applies to your diagnosis, that pathway is far more predictable. If only a trial pathway fits your case, we will tell you honestly what the realistic odds look like before you commit to anything — including if we believe a trial is unlikely to accept you.

Plan for a minimum of 4–6 weeks, with 6–8 weeks being more realistic. The breakdown: hospital assessment (3–5 days), leukapheresis and manufacturing wait (7–21 days), bridging therapy if needed (varies), conditioning chemotherapy (2–5 days), infusion (1 day), post-infusion monitoring (14–28 days).

You cannot leave China during the manufacturing period. The hospital needs to monitor your condition and manage disease with bridging therapy if needed. China Care coordinates hospital-adjacent accommodation for patients and caregivers.

It depends on why you are asking. If you relapsed after a previous CAR-T infusion, you may still be eligible for a second product, especially if the first targeted CD19 and a second targets CD22 or BCMA. This is an active area of clinical research in China.

If you want a second infusion with the same product for the same indication, eligibility is more restricted and depends on your T-cell health and disease status. Submit your case and we will review the options honestly, including telling you if China is not the right next step.

Free Initial Guidance is provided by China Care — free of charge. No hospital is involved at this stage. We review your diagnosis, prior treatment lines, and objectives, and identify which pathway (commercial product or clinical trial) may be appropriate. We also identify any missing documents. This is not a medical opinion.

The specialist consultation is a paid medical service at the hospital. China Care coordinates the appointment, prepares your records, arranges translation and an interpreter, and provides a written summary after the consultation. The hospital charges a registration fee. China Care charges a separate coordination fee. The physician's recommendation from the consultation is the authoritative medical determination of eligibility — not China Care's initial guidance.

For Free Initial Guidance: (1) latest pathology report confirming diagnosis and subtype, (2) treatment history including prior lines, drugs received, and response/relapse timeline, (3) most recent blood panel and LDH if available. Full medical records are not needed at this stage.

Once the specialist consultation is arranged, the hospital will request a more complete package including imaging reports and bone marrow biopsy results. China Care identifies what is missing and assists with translation of all documents before submission.

China Care charges a fixed coordination fee directly to the patient: USD 3,500 for CAR-T or bone marrow transplant coordination; USD 2,000 for other cancer treatment. Free Initial Guidance is free. The hospital specialist consultation incurs a separate hospital registration fee, which is charged directly by the hospital.

Treatment costs are quoted directly by the hospital and paid directly to the hospital. China Care never adds to, inflates, or marks up those costs. Our recommendation is based on clinical fit. Our coordination fee is the same regardless of which hospital you attend. All fees are disclosed in writing before you commit to anything.

This is a real risk and we take it seriously. Before any patient travels, we conduct a pre-screening review of medical records. We will not recommend travel if we believe the hospital is likely to decline. That said, the hospital makes the final eligibility determination on arrival; occasionally a patient's condition changes between submission and arrival.

In those cases, we work with the hospital to identify alternative options: a different product, a clinical trial, or a different treatment modality. We do not leave patients stranded. This is why we remain involved throughout, not just until you arrive.

As of June 2026, yes for one specific indication. On 22 June 2026, China's NMPA approved satricabtagene autoleucel (brand name Kelimei; manufactured by CARsgen Therapeutics, Shanghai) — the world's first commercially approved CAR-T product for a solid tumour. It is indicated for CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of treatment. This is a narrow, biomarker-specific approval — not a general solid tumour treatment.

Outside this specific indication, CAR-T for solid tumours remains an active area of clinical trial research in China, with trials targeting lung, liver, and other cancers. Outcomes in these trials are less predictable than for the approved haematological and gastric products. If your solid tumour is CLDN18.2-positive and HER2-negative, ask us to check eligibility for the approved product first, before considering a clinical trial pathway. For other solid tumours, we may also recommend considering other advanced therapies available in China such as TCR-T, NK cell therapy, or neoantigen vaccine programmes.

Yes, regardless of nationality. International patients seeking treatment in China require an S2 medical visa for stays under 180 days — the standard visa for most CAR-T treatment visits — or an S1 visa for longer-term treatment programmes. Both require an official hospital invitation letter.

The official invitation letter can only be issued by the licensed Chinese hospital treating you, on hospital letterhead with an official stamp — China Care cannot issue this document, but we coordinate with the hospital to secure it and guide you through the rest of the application. Requirements are similar for Canadian, German, Singaporean, and Brazilian passport holders; processing times vary by embassy. See our complete medical visa guide for 2026 for step-by-step instructions.